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Introduction
Long-term management of moderate-to-severe psoriasis, a chronic inflammatory skin disease, is usually discussed in terms of continuous administration. 1, 2 However, treatment interruptions may occur in clinical practice owing to infection, pregnancy, compliance issues, scheduled drug-free intervals or insurance coverage, etc. [1] [2] [3] [4] Psoriasis plaques frequently relapse when oral and biologic systemic treatments are interrupted, and retreatment may be insufficient to recapture initial response.
Therefore, thorough assessment of the efficacy and safety of biologic therapies during treatment withdrawal and retreatment is important to provide useful data for physicians in case they need to interrupt treatment in routine clinical practice. Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A. 9 It has been widely approved for the treatment of plaque psoriasis and psoriatic arthritis, and it is also approved for generalized pustular psoriasis and erythrodermic psoriasis in Japan. The effectiveness of continuous ixekizumab treatment for moderate-to-severe plaque psoriasis has been demonstrated in several phase III studies (UNCOVER-1, UNCOVER-2 and UNCOVER-3). 10, 11 Treatment withdrawal after 12 weeks of ixekizumab was assessed in a pooled analysis of responding patients [Static Physician Global Assessment (sPGA) of 0 or 1 at Week 12] in UNCOVER-1 and UNCOVER-2. 12 Most patients who were withdrawn from ixekizumab treatment relapsed (sPGA ≥3), and the majority of these patients recaptured response after 24 weeks of retreatment. These results suggest that ixekizumab can restore clinical response upon retreatment; although longer-term data (>12 weeks of continuous therapy before treatment withdrawal and >24 weeks of retreatment) addressing the efficacy and safety of interrupted ixekizumab treatment are lacking. Here we report the results of an analysis of a phase III trial (UNCOVER-J) that evaluated efficacy and safety outcomes among Japanese patients who were withdrawn after 52 weeks of treatment, and who were retreated with ixekizumab for up to 120 weeks after experiencing a relapse. Data up to 52 weeks in UNCOVER-J have been reported previously in Saeki et al.
13

Materials and methods
Study design
This was a phase III, multicentre, single-arm, open-label and long-term study (ClinicalTrials.gov number NCT01624233; first patient enrolled 21 June 2012). The protocol was approved by the local institutions' ethics committees and conforms to the provisions of the Declaration of Helsinki. All patients provided written informed consent. Data up to 24 weeks in UNCOVER-J were first reported in Saeki et al.
14
Study population
Eligibility criteria have been described in detail previously. 14 Key inclusion criteria for patients with plaque psoriasis were as follows: male and female Japanese patients with moderate-tosevere psoriasis, aged ≥20 years, confirmed diagnosis of the disease, a Psoriasis Area Severity Index (PASI) score ≥12, sPGA score ≥3 and ≥10% body surface area involvement at screening and baseline. 9 months after marketing authorization was received in Japan, all patients discontinued ixekizumab and entered post-treatment follow-up.) Patients who had completed the Retreatment Period or who were ongoing were counted as having completed the Retreatment Period. At the cut-off date for the Retreatment Period (3 April 2017), all completers had at least 120 weeks of retreatment.
Demographic and baseline clinical characteristics
The overall demographic and baseline clinical characteristics for patients with plaque psoriasis (N = 78) have been described previously. 13, 14 Demographic and baseline characteristics for the responder population (N = 70; Table 2 ) were consistent with those for the overall population with plaque psoriasis.
Efficacy outcomes
Induction dosing period For the responder population, all outcome measures showed improved efficacy from baseline to Week 12. At Week 12, PASI75, 90 and 100 response rates were 100%, 87% and 34% (NRI), respectively. At Week 12, sPGA (0,1) and sPGA (0) response rates were 90% and 39% (NRI), respectively. At baseline, mean PASI, DLQI and PSSI scores were 26.5, 10.4 Treatment withdrawal period For the responder population, all outcome measures showed reduced efficacy after ixekizumab treatment was withdrawn at Week 52. At Week 76 (24 weeks after ixekizumab withdrawal) and Week 100 (48 weeks after ixekizumab withdrawal), PASI75 response rates, which did not include retreatment data after relapse, were 26% and 7%, PASI90 response rates were 11% and 3%, and PASI100 response rates were 0% and 0% (NRI), respectively ( Fig. 3a) . At Week 100, sPGA (0,1) and sPGA (0) response rates were 4.3% and 0% (NRI), respectively (Fig. 3b) . For the 61 (87.1%) patients with PASI75 at Week 52 who relapsed (PASI ≤50) following the withdrawal of ixekizumab, the median time to relapse was 143 days. Of the 61 patients, for the patients with ≥PASI75~<90 (n = 8), ≥PASI90~<100 (n = 20) and PASI100 (n = 33) at Week 52, the median time to relapse was 85, 135 and 165 days, respectively. At Week 100, mean PASI, DLQI and PSSI scores increased to 5.7, 3.9 and 9.2, respectively.
Retreatment period For the relapse population, all outcome measures showed improved efficacy with ixekizumab retreatment and were maintained up to 120 weeks. At Week 12 and Week 120 of retreatment, PASI75 response rates were 83% and 83%, PASI90 response rates were 68% and 68%, and PASI100 response rates were 25% and 39% (NRI), respectively (Fig. 4a) . At Week 12 and Week 120 of retreatment, sPGA (0,1) response rates were 69% and 68%, and sPGA (0) response rates were 27% and 41% (NRI), respectively (Fig. 4b) . At Week 0 of retreatment, mean PASI, DLQI and PSSI scores were 17.9, 9.5 and 24.0, respectively, which improved to 2.9, 2.7 and 2.6 at Week 12 of retreatment, respectively, and were maintained at Week 120 of retreatment (1.9, 1.6 and 2.5, respectively).
Safety
Treatment withdrawal period For the responder population, approximately half of patients who withdrew from ixekizumab treatment reported DEAEs during the Treatment Withdrawal Period, during which ixekizumab was not administered to patients (Table 3 ). The most common DEAEs were viral upper respiratory tract infections [6/70 (8.6%)], followed by influenza, 
Discussion
This is the first clinical study to report long-term data on ixekizumab treatment withdrawal and retreatment in patients with moderate-to-severe psoriasis. We found that Japanese patients who previously responded to continuous ixekizumab treatment (PASI75 at Week 52) showed reduced efficacy in all parameters after ixekizumab withdrawal, with approximately half of patients relapsing within 5 months of treatment interruption. However, there were eight patients who completed the entire Treatment Withdrawal Period to Week 100 without relapse. Further, by Week 12 of ixekizumab retreatment (80 mg every 4 weeks), we observed an improvement in all efficacy parameters including PASI and DLQI scores and maintenance of response up to Week 120 of retreatment. Notably, improvements during retreatment occurred without use of the approved loading (160 mg) or induction doses for ixekizumab (80 mg every 2 weeks). Furthermore, we found that PSSI scores generally showed the same pattern of improvement as PASI scores with treatment withdrawal and retreatment. Ixekizumab was also well tolerated, with no new safety concerns identified during treatment withdrawal or retreatment. These results highlight the potential of ixekizumab as a treatment for Japanese patients with moderate-to-severe psoriasis under conditions that reflect the treatment interruptions that might occur in clinical practice.
In this analysis of UNCOVER-J, response and relapse criteria were based on PASI scores in accordance with both the primary endpoint for the overall study (PASI75 at Week 12) 14 and common practices in clinical trials in Japan. Although different response criteria were used in our earlier pooled analysis of ixekizumab treatment interruption, 12 the findings for Japanese patients in the current study were generally similar to the global Patients with multiple occurrences of the same event were counted under the highest severity; in the case where the severity has an additional category 'more severe than baseline' collected, the 'more severe than baseline' and 'severe' categories were combined for analysis and presentation. Of the 70 patients who entered the Treatment Withdrawal Period, three patients did not enter the following Retreatment Period (one patient who discontinued owing to an AE before Week 100 but did not relapse; one patient who discontinued owing to a physician decision before Week 100 and relapsed; one patient who relapsed before Week 100 but did not enter the Retreatment Period owing to a physician decision). Of these 70 patients, 61 patients relapsed during the Treatment Withdrawal Period. A total of 59 patients who relapsed during the Treatment Withdrawal Period and who entered the following Retreatment Period were included in the relapse population. AE, adverse event; AESI, adverse event of special interest; DEAE, drugfree-emergent adverse event; IXE Q4W, 80 mg ixekizumab every 4 weeks; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
population. In the earlier pooled analysis, responders were defined as those who achieved sPGA (0,1) at Week 12. Similar to the current study, we observed that among patients interrupting treatment at Week 12, most (>80%) had relapsed (sPGA ≥3) with treatment withdrawal by Week 60, with a median time to relapse of approximately 20 weeks. Further, 80%, 56% and 35% (observed) of patients recaptured a PASI75, 90 and 100 at 12 weeks of retreatment, respectively, and response rates were maintained to Week 24 of retreatment in our pooled analysis.
The results of the current study confirm our earlier findings and may be considered to more closely replicate clinical practice (longer-term period of treatment before treatment discontinuation), but importantly they show that response rates are maintained with long-term retreatment (up to 120 weeks). In addition, irrespective of the selected response/relapse criteria and differences in timing of treatment withdrawal (i.e. Week 12 for the UNCOVER studies and Week 52 in the current study), results from both studies show that most patients relapse with ixekizumab withdrawal and recapture the response with retreatment. However, not all patients recaptured the same degree of efficacy when ixekizumab was re-introduced. The approved loading (160 mg) and induction doses (80 mg every 2 weeks) of ixekizumab were not used for retreatment in both studies, and the impact of these doses on clinical outcomes could not be evaluated. Further evaluation of interrupted ixekizumab therapy with different treatment strategies (e.g. withdrawal times and doses) is warranted.
Studies of other IL-17 inhibitors using different treatment strategies demonstrate varying relapse and recapture of response profiles with interrupted therapy. A pooled analysis of the ERASURE and FIXTURE trials of secukinumab, including patients who achieved PASI75 at Week 52, demonstrated that most patients relapsed (loss of >50% of the maximum PASI gain compared with baseline) and recaptured response with retreatment. 16 Only 16% (secukinumab 300 mg-placebo treatment group) of patients did not relapse after treatment withdrawal, and the median time to relapse was approximately 28 weeks. Upon retreatment using weekly dosing to Week 3 and every 4 weeks thereafter, 95%, 70% and 38% of patients recaptured PASI75, 90 and 100, respectively, at Week 12. The SCULPTURE trial of secukinumab, using retreatment-asneeded vs. a fixed-interval maintenance regimen, demonstrated that most responding patients (PASI75 at Week 12) relapsed with treatment withdrawal. 7 Overall, 85% (secukinumab 300 mg retreatment-as-needed group) relapsed (loss of >20% of the maximum PASI gain compared with baseline), and the median time to relapse was approximately 24 weeks. Most patients recaptured response with retreatment (69% recaptured PASI75 at first retreatment and 91% of patients recaptured PASI75 at Week 12) . A pooled analysis of the AMAGINE-1, AMAGINE-2 and AMAGINE-3 trials of brodalumab, an anti-IL-17 receptor antibody, demonstrated more rapid relapse upon treatment discontinuation compared with the anti-IL-17 antibodies, ixekizumab and secukinumab. 17 At brodalumab treatment discontinuation, 96% of patients had achieved PASI75. Median time to relapse (defined as the request of a patient to initiate a new treatment after brodalumab withdrawal) was 6-7 weeks, and only 22% of patients had not relapsed at 3 months (all had relapsed by 9 months). Brodalumab retreatment was not conducted. Differences in response/relapse criteria make strict comparison between these studies difficult. However, similar to ixekizumab, the results from these studies 7, 16, 17 show a loss of response with treatment withdrawal and recapture of response with retreatment, with lower response rates than initial treatment. Some studies have shown an increased risk for the development of ADAs with intermittent therapy with biologics. 4, [18] [19] [20] In the current study, the incidence of TE-ADAs during the initial 52-week Maintenance Treatment Period was 12.8% (10/78), while the incidence of TE-ADAs during the Retreatment Period (maximum 192 weeks) was 19.4% (13/67). Taking into account the longer duration of the Retreatment Period, the incidence of TE-ADAs during the Retreatment Period has not increased from that of the initial 52-week Maintenance Treatment Period. In addition, similar to a previous study of interrupted ixekizumab therapy, 12 few patients in the current study developed neutralizing antibodies. In the previous study of ixekizumab, there were no meaningful differences in the per cent PASI improvement upon retreatment in patients with or without TE-ADAs. 12 Considering the small number of evaluated patients, the absence of a reference arm and the open-label nature of the current study, no additional conclusions can be drawn. Important strengths of this analysis include the prospective and multicentre design of the UNCOVER-J study, the low discontinuation rate and the length of follow-up with retreatment. However, there are several limitations to this analysis that are inherent in the study design, including the lack of a control group, open-label treatment, and the fact that the study was conducted in Japanese patients only, with a relatively small sample size.
In conclusion, we found that in Japanese patients with an initial response to ixekizumab, approximately half relapsed within 5 months of treatment withdrawal; however, most of them subsequently recaptured responses within 12 weeks, and that response was maintained up to 120 weeks of retreatment. Furthermore, interrupted ixekizumab therapy was well tolerated.
